NCT00233545已完成2 期
Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia
AB Foundation2 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2005年9月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 80
- 试验地点
- 2
- 主要终点
- cure rate
研究概览
简要总结
Cutaneous leishmaniasis is typically treated with the parenteral product pentavalent antimony. Miltefosine is an oral agent shown to be active for mucosal leishmaniasis due to L braziliensis in Bolivia and cutaneous leishmaniasis due to L panamensis in Colombia. This trial is intended to evaluate miltefosine for cutaneous leishmaniasis due to L braziliensis in Bolivia. Patients will be randomly assigned to miltefosine or pentavalent antimony. Standard dose regimens will be used for both drugs.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 3 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Presentation: At least 1 lesion must be ulcerative. Parasitology: Parasitological confirmation of 1 lesion will be made by visualization or culture of leishmania from the biopsy or aspirate of the lesion.
- •Previous RX: No specific or putatively specific therapy for leishmaniasis (Sb, pentamidine, amphotericin B, imidazoles, allopurinol)
- •Other diseases: No concomitant diseases by history and by approximately normal complete blood counts (white blood count, hemoglobin, platelet count), values of liver transaminases (SGOT) and kidney function tests (creatinine).
排除标准
- 未提供
结局指标
主要结局
cure rate
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Miltefosine and GM-CSF in Cutaneous LeishmaniasisCutaneous LeishmaniasisNCT03023111Hospital Universitário Professor Edgard Santos300
Unknown
不适用
Study of Cases of Cutaneous Leishmaniasis Treated With Miltefosine in French Guiana, Retrospective StudyCutaneous LeishmaniasesTreatment AdherencePrimary Health CareDrug EvaluationNCT05493059Centre Hospitalier de Cayenne20
已完成
2 期
Miltefosine Plus IL Pentamidine for Bolivian CLLeishmaniasis, CutaneousNCT03445897Jonathan Berman50
已完成
2 期
Miltefosine to Treat Mucocutaneous LeishmaniasisMucosal LeishmaniasisCutaneous LeishmaniasisNCT01050907Knight Therapeutics (USA) Inc4
已完成
1 期
Miltefosine for Mucosal LeishmaniasisLeishmaniasisNCT00373776AB Foundation75